We are leveraging microfluidic technologies integrated with electronic sensors to probe the dynamic response of the endothelium to mechanical and chemical stimuli in a spatiotemporal manner. 

Conventional delivery of naked drugs to treat unhealthy cells in atherosclerotic plaques has been limited not only because it is difficult to transport an accurate dose of drugs to desired sites but also because drugs injected often accumulate where they shouldn’t belong, leading to adverse side effects. To address this problem, our current project using our custom microfluidic transcellular monitor is to engineer HDL-mimetic vehicles with biological molecules that can interact with diseased cells in desired sites and that can genetically engineer the cells to function correctly, eventually treating atherosclerosis.